The first award under this contract is a $2.5 million task order from NASA's In Space Production Applications (InSPA) program. The order funds expanded drug development investigations on the ISS using Redwire's proprietary PIL-BOX technology, designed to accelerate space-based pharmaceutical research.

Redwire will manage, integrate, and support a wide range of NASA-funded scientific studies conducted in orbit. These efforts encompass life sciences and materials sciences investigations that rely on the unique advantages of microgravity to produce insights unattainable on Earth.

"Redwire's biotechnology facilities have been an integral part of NASA's ISS research strategy, supporting an increased throughput of critical scientific research and expanding on-orbit capabilities to accommodate cutting-edge science in drug development, cancer research, and tissue engineering," said John Vellinger, President of Redwire In-Space Industries. "As the sole recipient for this IDIQ contract, Redwire is grateful for NASA's continued trust in our proven biotechnology capabilities and experience, and we are committed to enabling new discoveries for NASA and the ISS science community."

Redwire has decades of heritage in microgravity research, having supported hundreds of investigations on both the Space Shuttle and the ISS. The company provides biotechnology and pharmaceutical research solutions in space, working with commercial partners to explore new therapeutics and accelerate innovation. Notable collaborators include Bristol Myers Squibb, Eli Lilly and Company, and Butler University.

Recently, Redwire launched a new initiative called SpaceMD, aimed at producing seed crystals in orbit for development of novel and reformulated medicines on Earth, further expanding the company's role in space-enabled healthcare innovation.

Related Links
Redwire
Space Medicine Technology and Systems